Title:Pharmacological Considerations during Percutaneous Treatment of Heart
Failure
Volume: 30
Issue: 8
Author(s): Jose Antonio Sorolla-Romero, Javier Navarrete-Navarro, Julia Martinez-Sole, Hector M. Garcia Garcia, Jose Luis Diez-Gil, Luis Martinez-Dolz and Jorge Sanz-Sanchez*
Affiliation:
- Department of Cardiology, Hospital Universitari i Politècnic La Fe, Avenida Fernando Abril Martorell 116, Valencia, Spain
Keywords:
Heart failure, interventional cardiology, Impella, cardiogenic shock, TandemHeart, ECMO, MitraClip, TriClip.
Abstract: Heart Failure (HF) remains a global health challenge, marked by its widespread prevalence and substantial
resource utilization. Although the prognosis has improved in recent decades due to the treatments implemented,
it continues to generate high morbidity and mortality in the medium to long term. Interventional
cardiology has emerged as a crucial player in HF management, offering a diverse array of percutaneous treatments
for both acute and chronic HF. This article aimed to provide a comprehensive review of the role of percutaneous
interventions in HF patients, with a primary focus on key features, clinical effectiveness, and safety
outcomes. Despite the growing utilization of these interventions, there remain critical gaps in the existing
body of evidence. Consequently, the need for high-quality randomized clinical trials and extensive international
registries is emphasized to shed light on the specific patient populations and clinical scenarios that stand to
benefit most from these innovative devices.
